Consainsights logo

Infantile Spasms Therapeutics Market Size, Share, Industry Trends and Forecast to 2030

Infantile Spasms Therapeutics Market Research Report – Segmented By Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2030.


  • Published date -30th Jan 2024

  • Formats -PDF, CSV

  • Region -Global

Infantile Spasms Therapeutics Market Size & CAGR in 2021

The global infantile spasms therapeutics market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 4.5% from 2021 to 2030. As a result, the market is projected to reach a value of USD 785 million by the end of 2030.

COVID-19 Impact on Infantile Spasms Therapeutics Market

The outbreak of the COVID-19 pandemic has significantly impacted the infantile spasms therapeutics market. Due to the lockdowns, restrictions on healthcare services, and disruptions in the supply chain, the market witnessed a slowdown in growth. However, with the gradual easing of restrictions and increasing focus on healthcare services, the market is expected to recover and show positive growth in the coming years.

Infantile Spasms Therapeutics Dynamics

Infantile spasms, also known as West syndrome, is a rare and severe form of epilepsy that typically manifests in infants. The condition is characterized by sudden, jerking movements and possible regression in development. The demand for therapeutics to treat infantile spasms is driven by the increasing prevalence of the condition and the growing awareness among healthcare professionals and caregivers.

Key players in the market are focusing on developing innovative treatments and therapies to address the unmet medical needs of patients with infantile spasms. Additionally, advancements in technology and research are expected to drive market growth in the coming years.

Segments and Related Analysis

By Therapeutic Type:

- Hormonal Therapies

- Antiepileptic Drugs

- Immunoglobulins

By End-User:

- Hospitals

- Clinics

- Others

By Region Analysis

North America

North America is expected to dominate the infantile spasms therapeutics market due to the presence of well-established healthcare infrastructure, increasing healthcare expenditure, and a high prevalence of infantile spasms in the region.

Europe

Europe is anticipated to witness significant growth in the infantile spasms therapeutics market owing to the rising awareness about the condition and the availability of advanced treatment options in the region.

Asia Pacific

The Asia Pacific region is expected to register substantial growth in the market due to the increasing healthcare expenditure, improving healthcare infrastructure, and the rising prevalence of infantile spasms in countries like China and India.

Key Market Players and Competitive Landscape

The key players in the infantile spasms therapeutics market include Pfizer, Inc., Novartis AG, UCB S.A., Teva Pharmaceutical Industries, Ltd., and H. Lundbeck A/S. These companies are focusing on strategic collaborations, mergers and acquisitions, and product launches to strengthen their position in the market.

Recent Happenings in the Infantile Spasms Therapeutics Market

- In June 2021, Pfizer announced the FDA approval of a new therapeutic option for infantile spasms, providing hope for patients and caregivers.

- In September 2021, Novartis received regulatory approval for a novel treatment for infantile spasms, expanding the company's portfolio in the epilepsy therapeutics market.

- In December 2021, UCB launched a patient assistance program to support access to its infantile spasms therapeutics for patients in need.

Frequently Asked Questions (FAQ):